SPPARM Trademark

Trademark Overview


On Friday, February 10, 2023, a trademark application was filed for SPPARM with the United States Patent and Trademark Office. The USPTO has given the SPPARM trademark a serial number of 79367704. The federal status of this trademark filing is REGISTERED as of Tuesday, September 26, 2023. This trademark is owned by KOWA COMPANY, LTD.. The SPPARM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, pharmaceutical preparations for treatment of fatty liver and steatohepatitis, pharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorders, pharmaceutical preparations for the treatment of digestive system disease, pharmaceutical preparations for the treatment of primary biliary cirrhosis, pharmaceutical preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, pharmaceutical preparations for the treatment of liver disease, pharmaceutical preparations for the treatment of metabolic disease, pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, analgesics; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, resp...
spparm

General Information


Serial Number79367704
Word MarkSPPARM
Filing DateFriday, February 10, 2023
Status700 - REGISTERED
Status DateTuesday, September 26, 2023
Registration Number7172010
Registration DateTuesday, September 26, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 11, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, pharmaceutical preparations for treatment of fatty liver and steatohepatitis, pharmaceutical preparations for the treatment of cardiovascular disorders and metabolic disorders, pharmaceutical preparations for the treatment of digestive system disease, pharmaceutical preparations for the treatment of primary biliary cirrhosis, pharmaceutical preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, pharmaceutical preparations for the treatment of liver disease, pharmaceutical preparations for the treatment of metabolic disease, pharmaceutical preparations for the prevention and treatment of disorders of the metabolic system, analgesics; pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital or anal conditions; veterinary preparations, namely, veterinary preparations for the treatment of diseases of the circulatory system and diabetes-related diseases, veterinary preparations for treatment of fatty liver and steatohepatitis, veterinary preparations for the treatment of cardiovascular disorders and metabolic disorders, veterinary preparations for the treatment of digestive system disease, veterinary preparations for the treatment of primary biliary cirrhosis, veterinary preparations for the treatment of fatty liver and liver hepatitis and liver cirrhosis, veterinary preparations for the treatment of liver disease, veterinary preparations for the treatment of metabolic disease, veterinary preparations for the prevention and treatment of disorders of the metabolic system, analgesics; veterinary pharmaceutical and biological preparations for the treatment of diseases of the central nervous system, peripheral nervous system, sensory organs, the circulatory system, respiratory system, and the digestive system; veterinary pharmaceutical substances for the treatment of dermatological diseases, allergies and urogenital or anal conditions; sanitary preparations for medical use; anti-inflammatory agents, namely, topical preparations in the form of gels and salves, adhesive skin patches, liquid formulations, cream and sprays, all for relieving pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 21, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKOWA COMPANY, LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP

Party NameKOWA COMPANY, LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP

Party NameKOWA COMPANY, LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events


Event DateEvent Description
Monday, November 20, 2023NOTIFICATION PROCESSED BY IB
Friday, October 27, 2023FINAL DISPOSITION NOTICE SENT TO IB
Friday, October 27, 2023FINAL DISPOSITION PROCESSED
Thursday, October 26, 2023GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Tuesday, September 26, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, July 11, 2023NOTIFICATION PROCESSED BY IB
Tuesday, July 11, 2023PUBLISHED FOR OPPOSITION
Tuesday, June 20, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, June 21, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, June 21, 2023NOTICE OF PUBLICATION
Wednesday, June 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 25, 2023ASSIGNED TO EXAMINER
Tuesday, April 25, 2023APPLICATION FILING RECEIPT MAILED
Friday, April 21, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 20, 2023LIMITATION FROM ORIGINAL APPLICATION ENTERED
Friday, April 14, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB